All News

The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.

Any increase in lipoprotein(a) levels was linked to increased risk of myocardial infarction and stroke; women and Black adults are most likely to be affected.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.

Your daily dose of the clinical news you may have missed.

Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.

ZORYVE® (roflumilast) cream 0.15% is a once-daily, steroid-free PDE4 inhibitor approved for the treatment of mild to moderate atopic dermatitis in patients aged 6 and older. Clinical trials demonstrate its rapid onset, strong efficacy, and favorable safety profile, with emerging evidence supporting its use in younger children and as a long-term maintenance therapy to prevent flares.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

Primary care clinicians are on the frontline of detecting early cognitive decline. Help us understand your challenges by taking this short survey.

The new findings are contrary to previous research that found family history of AD increases desire for testing and support the "right not to know."

Your daily dose of the clinical news you may have missed.

Rates of amputation in Black Americans with peripheral arterial disease are 3-times higher than that of their White counterparts. Dr Fakorede, discusses, here.

New data from UNITE study suggest fremanezumab was effective in alleviating migraine and comorbid MDD in patients with both conditions.

The increase in stool-based CRC testing is a logical trend, Hendrick said in an interview, given the convenience plus the 2 million younger adults now eligible for screening.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

Life expectancy increased steadily in the US West and Northeast across the 20th century, but gains were just minimal in Southern states, according to the findings.